Our Methodology

Transparency in how we evaluate, rank, and present peptide research information.

Our Scoring Framework

Every peptide in our database is evaluated across four weighted pillars. These pillars were designed to balance scientific rigor with practical relevance, ensuring our rankings reflect both the strength of the evidence and the real-world significance of each compound.

Evidence Quality

40%

The largest component of our score. We assess FDA approval status, the quality and phase of clinical trial data, the total number of peer-reviewed publications, and whether findings have been independently replicated. Peptides with FDA-approved indications and large randomized controlled trials score highest in this category.

Safety Profile

25%

We evaluate known side effects, documented drug interactions, acute and chronic toxicity data, post-marketing surveillance reports, and the overall risk-benefit characterization. Peptides with extensive long-term safety data and well-characterized side effect profiles receive higher scores.

Research Maturity

20%

This pillar considers how long the peptide has been studied, the number of independent research groups investigating it, the geographic diversity of research efforts, and the reproducibility of key findings across different laboratories and study populations.

Community Consensus

15%

While anecdotal evidence alone does not drive our rankings, we recognize the value of real-world experience. This pillar incorporates aggregated user experience reports, practitioner feedback and prescribing patterns, search interest and community discussion volume, and expert opinion from published reviews.

Evidence Classification System

We classify the evidence supporting each peptide into five tiers. This system helps readers quickly understand the strength of the scientific foundation behind any given compound.

Tier 1

FDA Approved

The peptide has received FDA approval for at least one clinical indication. This represents the highest level of regulatory validation, requiring demonstration of safety and efficacy in large-scale clinical trials. Examples: Semaglutide, Tirzepatide, Bremelanotide (PT-141).

Tier 2

Human Clinical Trials

The peptide has been studied in controlled human clinical trials (Phase 1-3) with published results in peer-reviewed journals, but has not yet received FDA approval. The data may support efficacy but regulatory review is pending or not pursued. Examples: Retatrutide, CJC-1295, Epithalon.

Tier 3

Animal Studies

Evidence is primarily based on in vivo animal studies (rodents, primates, etc.). While animal models provide important biological insights, results do not always translate to humans. Many popular research peptides fall into this category. Examples: BPC-157, TB-500, GHK-Cu (systemic).

Tier 4

In Vitro / Cell Studies

Evidence comes primarily from laboratory studies using cell cultures or tissue samples. These studies provide mechanistic insights but are the furthest removed from real-world clinical outcomes.

Tier 5

Anecdotal / Theoretical

Evidence is based primarily on user reports, practitioner observations, or theoretical extrapolation from related compounds. While valuable as hypothesis generators, anecdotal evidence alone does not establish efficacy or safety.

Our Review Process

Each peptide profile undergoes a structured review before publication:

Literature Survey

We conduct a systematic search of PubMed, Google Scholar, and clinical trial registries (ClinicalTrials.gov) to identify all relevant published research for the peptide.

Data Extraction

Key findings, dosing data, safety outcomes, and regulatory information are extracted and cross-referenced across multiple sources to ensure accuracy.

Expert Contextualization

Our editorial team places findings in context, distinguishing between preliminary and established results, and noting limitations such as small sample sizes or single-lab replication.

Scoring and Ranking

Each peptide is scored across our four-pillar framework. Rankings are generated from composite scores and reviewed for internal consistency.

Publication and Monitoring

Profiles are published and entered into our monitoring queue for periodic review. Significant new publications or regulatory actions trigger immediate reassessment.

Editorial Independence

No vendor affiliations. 50 Best Peptides does not accept payment, sponsorship, or free products from peptide vendors, compounding pharmacies, or pharmaceutical companies in exchange for favorable rankings or coverage.

No sponsored rankings. Our peptide rankings are determined solely by our scoring framework. No company or individual can pay to influence a peptide's position in our database.

Transparent sourcing. We cite the research that informs our profiles. Where data is limited or contested, we say so explicitly. We do not selectively highlight positive findings while omitting negative or inconclusive results.

Conflict disclosure. If 50 Best Limited has any commercial relationship relevant to a specific peptide (such as our skincare shop featuring peptide-infused products), this is clearly disclosed and does not influence research content or rankings.

Update Policy

The peptide landscape evolves rapidly. New clinical trials are published, regulatory agencies take action, and our understanding of these compounds deepens over time. Our update policy is designed to keep our database current:

Quarterly Reviews

Every peptide profile is reviewed at least once per quarter. We check for new publications, updated clinical trial results, and changes in regulatory status.

Triggered Updates

Certain events trigger immediate profile updates: FDA approval or rejection decisions, safety alerts, publication of pivotal clinical trial results, and major regulatory reclassifications (such as the 2026 FDA Category 1 reclassification of BPC-157).

Ranking Recalibration

Rankings are recalculated quarterly based on updated scores. Significant movements (more than 5 positions) are noted in the profile and may be discussed in our blog.

Version History

Major changes to peptide profiles are logged internally. If a peptide's ranking changes significantly or new safety information emerges, we document the rationale for the update.

A note on humility. Peptide science is a rapidly evolving field. Despite our best efforts, our understanding of any given compound is necessarily incomplete. We present the best available evidence as we understand it, and we welcome corrections, suggestions, and feedback from the research community. If you believe a profile contains an error or omits important information, please contact us.